These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31821858)

  • 1. Regulations, liability, safety, and economics related to compounding.
    Campbell EH; Elston DM; Straughan CL; Antonovich DD
    J Am Acad Dermatol; 2020 Jul; 83(1):184-188. PubMed ID: 31821858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the clinical indications, general principles and techniques related to compounding.
    Campbell EH; Elston DM; Straughan CL
    J Am Acad Dermatol; 2020 Jul; 83(1):179-183. PubMed ID: 31669439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
    Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compounding for women's health: a compounder's perspective - need, regulations, and future.
    Boomsma D; Lahoud G
    Climacteric; 2021 Feb; 24(1):32-37. PubMed ID: 33135943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Veterinary compounding in small animals: a clinical pharmacologist's perspective.
    Boothe DM
    Vet Clin North Am Small Anim Pract; 2006 Sep; 36(5):1129-73, viii. PubMed ID: 16984830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward Better-Quality Compounded Drugs - An Update from the FDA.
    Woodcock J; Dohm J
    N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
    [No Abstract]   [Full Text] [Related]  

  • 14. Compounding botanicals: a legal perspective.
    Valentino JG; Bormel FG
    J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Current Landscape of Veterinary Compounding in the Veterinary Setting.
    Gochenauer AE; Rishniw M; Holmes ER; Forsythe LR
    Int J Pharm Compd; 2019; 23(5):428-433. PubMed ID: 31513543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sterile products: advances and challenges in formulation, manufacturing and regulatory aspects--a regulatory review perspective.
    Hussong D
    AAPS PharmSciTech; 2010 Sep; 11(3):1482-4. PubMed ID: 20845091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extemporaneous compounding activities and the associated informational needs of pharmacists.
    Crawford SY; Dombrowski SR
    Am J Hosp Pharm; 1991 Jun; 48(6):1205-10. PubMed ID: 1858798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Expands List of "Do Not Compound" Drug Products.
    Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services
    J Pain Palliat Care Pharmacother; 2017 Mar; 31(1):76-78. PubMed ID: 28287350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compounding and Comparative Study of a Superior, Faster, and More Adaptable Lidocaine Dental Gel Formulation.
    Rashid M; Hossain MF; Nounou M; Rahman M; Sarkar S; Adeyemo A; Mullins R
    Int J Pharm Compd; 2019; 23(3):250-257. PubMed ID: 31085794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary pharmaceutical compounding.
    Allen LV
    Ann Pharmacother; 2003 Oct; 37(10):1526-8. PubMed ID: 14519042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.